Clinical Trials Browser

Solid Tumors

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

764 enrolled

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

aCCeleR8-001

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

RAINFOL-01

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

COMBINE-EGFR-1

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)